Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim to undertake phase III BIBW 2992 trial

Boehringer Ingelheim to undertake phase III BIBW 2992 trial

4th August 2009

Boehringer Ingelheim is to initiate a phase III trial into the role of BIBW 2992 (Tovok) as a first-line treatment for non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations.

The firm made its announcement at the International Association for the Study of Lung Cancer’s 13th World Conference on Lung Cancer.

Both the safety and efficacy of BIBW 2992 will be compared to standard chemotherapy (cisplatin/pemetrexed) as a potential first-line therapy for patients in the LUX-Lung 3 trial.

James Yang, professor at the Graduate Institute of Clinical Medicine and the Graduate Institute of Clinical Pharmacy at the College of Medicine at the National Taiwan University, said that the trial will be “important”.

“BIBW 2992 is an irreversible tyrosine kinase inhibitor whose clinical benefit we are hoping to confirm in the first-line setting for patients with EGFR mutations,” he added.

In recent days, Boehringer Ingelheim announced that its ARTEN trial showed non-inferiority in relation to efficacy between Viramune (nevirapine) and ritonavir boosted atazanavir (atazanavir/r), when both were combined with emtricitabine (Truvada) and tenofovir.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.